Regulus Therapeutics Surges 11% Amid Deutsche Bank Report

By: via Benzinga
Deutsche Bank initiated coverage on Regulus Therapeutics Inc (NASDAQ: RGLS) in a report issued Monday with a Buy rating and $30 price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.